Home » Cancer Types » Lung Cancer
Lung Cancer
Lung Cancer News & Features
Immunotherapy prolonged survival compared with platinum chemotherapy.
Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone.
Researchers sought to determine the effectiveness of nivolumab, identify predictors of early discontinuation of treatment among patients with NSCLC, and determine median OS of nivolumab and docetaxel.
Pooled odds ratios for lung cancer increased with emphysema severity, and were higher for visual versus quantitative assessments on chest CT.
Segmentectomy prolonged 5-year overall survival in a phase 3 trial.
Load More
Lung Cancer Clinical Trials Load More
Open
Next post in Lung Cancer
Close
Close more info about Immunotherapy Confers Survival Benefit in NSCLC Patients With Brain Metastasis
Loading...
Close more info about Immunotherapy Confers Survival Benefit in NSCLC Patients With Brain Metastasis
Loading...